Participated · Series F · Oct 2024

Glooko operates a digital healthcare and life sciences platform that connects patients, providers, biopharma and medical device partners to improve chronic disease management. Its core product empowers people with diabetes to manage their condition and strengthens engagement with their healthcare teams. The company says more than 4.4 million people around the world with diabetes have used the Glooko platform. Glooko intends to use new funding to accelerate global product expansion and advance its life sciences work. The company is led by newly appointed CEO Mike Alvarez, who joins with extensive leadership experience in medical devices and biotechnology. The business emphasizes personalized, intelligent, connected care for people with chronic conditions. Glooko provides a digital platform for remote patient monitoring and chronic care management, with a particular focus on diabetes and obesity. Its software collects and aggregates data from blood‑glucose meters, continuous glucose monitors, insulin pumps, pens, and activity trackers to enable telehealth, clinical research, and clinician–patient collaboration. The platform is compatible with the vast majority of diabetes devices and is used by more than 7,500 clinics and over 3 million users in 27 countries across 20 languages. The company says proceeds will accelerate organic growth and strategic initiatives across its product line, increase adoption of its remote patient monitoring platform, widen commercialization in clinical research, and expand into additional therapy areas. Glooko reported strong traction in 2020, including partnerships with major healthcare systems and extended long‑term agreements with industry leaders such as Insulet and Novo Nordisk. The company is headquartered in Palo Alto, California, with a European headquarters in Gothenburg, Sweden. Glooko offers an FDA-cleared, HIPAA-compliant diabetes data platform that syncs with popular diabetes devices, wearables and activity trackers to provide reports and analytics. Its platform serves more than one million patients and supports over 6,000 providers across 27 countries. Glooko provides payers, employers, pharma and health systems with personalized, actionable insights aimed at improving outcomes and lowering costs. The company plans to expand sales, marketing and development teams and to increase commercialization in France, Germany, the U.K., Asia and the Middle East. Glooko is further developing data analytics and artificial intelligence capabilities to deliver personalized insights, prompts to drive behavior change, and clinical decision support for clinicians and coaches. The company says the new investment will accelerate growth and deepen its analytics expertise. Glooko, formed by the merger of Mountain View–based Glooko and Gothenburg–based Diasend, operates a unified diabetes management platform. The platform downloads data from more than 160 devices—including glucose meters, insulin pumps, continuous glucose monitors (CGMs) and activity trackers—and supports in-office data uploads, analytics, smartphone-enabled self-management, and a population health platform for diabetes coaches. The combined business enables in-clinic and remote diabetes management across 4,000 diabetes health systems, in 23 countries and 15 languages worldwide. Led by CEO Rick Altinger, the company will use the funds to accelerate integration and sales efforts. The company recently raised $8M in equity financing led by Canaan Partners, with participation from Social Capital, Samsung Ventures and Yogen Dalal. Glooko offers a unified diabetes data management platform that includes Bluetooth-enabled hardware (MeterSync) to import blood glucose readings from more than 30 proprietary meters and software tools for clinicians. It sells B2B to health systems and clinics, which furnish patients with Glooko hardware to enable remote monitoring. The software includes a Population Tracker with analytics and a module for predicting hypoglycemia unawareness; the company plans to integrate insulin pumps and continuous glucose monitors and to add personalized predictive algorithms using the new funding. Glooko launched its hardware device and app in 2011 and charges contracted health systems and clinics a per-patient-per-month (PMPM) subscription, with the fee decreasing at larger patient volumes. The company reports "thousands" of users and "millions" of blood glucose readings in its database to date.

Led · Series B · Sep 2023

Vivante Health provides virtual gastrointestinal care through its GIThrive platform, pairing data-driven technology with a coordinated team of physicians, registered dietitians and health coaches. The platform offers food and symptom logging, online educational resources, 24/7 access to dietitians, health coaches and nurses, and a nationwide network of internists and gastroenterologists for diagnosis, lab orders and prescriptions. Recent GIThrive enhancements add AI-driven personalized care plans that dynamically adjust to symptoms and other variables, helping bridge virtual and real-world care. The company plans to use the Series B proceeds to fund technology upgrades designed to predict the onset and progression of GI conditions and to expand its commercial and client support teams. Vivante will also invest in onboarding support for new employers, health plans and channel partners. The company is led by CEO Bill Snyder and is headquartered in Chicago, IL. Vivante Health offers an all-in-one gut health program, GIThrive, that combines technology, advanced science, and on-demand human support to improve digestive health and lower cost of care. Led by CEO Bill Snyder, the company delivers a digital solution for digestive health and disease. Vivante has partnerships with employer healthcare platforms such as Virgin Pulse and Accolade and serves clients including US Foods, Bucknell University, and Marpai. Since the beginning of 2021 the company grew its client base by 400% through the addition of key Fortune 500 clients. The company intends to use the Series A proceeds to expand operations and broaden its business reach. Vivante Health offers GIThrive, a digital digestive-health program combining at-home microbiome testing, a breath-based food-sensitivity monitor, 24/7 access to a gastrointestinal care team and additional self-management tools. The company positions GIThrive as a chronic-disease management tool tuned to individuals with gastrointestinal discomfort and illness. CEO and founder Dr. Kimon Angelides previously helped found EosHealth (later Livongo). Vivante maintains offices in Houston, Nashville, Chicago and Athens, Greece. The company has pursued selling GIThrive to health plans and employers and says the new funds will accelerate efforts to provide relief to thousands of Americans with chronic GI symptoms. The microbiome/gut wellness space includes competitors such as DayTwo and Bold Health, and the industry has been shadowed by the downfall of former frontrunner uBiome. Vivante Health offers a gut health management program called GIThrive that combines personalized nutrition plans, daily health challenges, "Med-ucation" to encourage prescription adherence, and on-demand care for symptom flares with 24/7 Gut-Side Assistance™. The platform pairs data science with access to digestive health experts to help individuals manage conditions. Dr. Kimon Angelides is the founder and CEO. The company announced a minority investment from NFP Ventures; the amount was not disclosed. No operating metrics or additional financial details were provided in the article. The company is headquartered in Houston, Texas.

Participated · Series D · Feb 2023

Clearsense provides a cloud-based, AI-enabled, and HITRUST-certified platform of data solutions focused on healthcare data governance, implementation, and analytics. The company is led by CEO Gene Scheurer and is headquartered in Jacksonville, FL. Clearsense raised $50M in a Series D to support its growth. Management says the funds will be used to invest in infrastructure, technology, and people to drive expansion of its platform. The business serves healthcare organizations seeking consolidated data and analytics capabilities. Alongside the financing, the company added Anthony Williams, a partner at HealthQuest, to its board. Clearsense is a healthcare data platform-as-a-service serving both providers and payers, led by co-founders Charles Boicey (Chief Innovation Officer) and Gene Scheurer (Chief Executive Officer). Its core product, the Clearsense DataHub, is described as a central nervous system for healthcare data that automates data curation, preparation, normalization, and governance. The platform operates adjunctively within any technology landscape so stakeholders can leverage disparate data sources to reduce costs, increase revenue opportunities, and improve outcomes. Clearsense also offers advisory services and is expanding its roster of industry experts in data governance, data science, research, and advanced analytics to help operationalize data across the enterprise. The company is based in Jacksonville, Fla., and recently raised new capital to fund product and services expansion.

Participated · Equity · Nov 2021

PierianDx builds assay-agnostic interpretation technology and services to help providers, laboratories, and medical centers run next-generation sequencing (NGS) testing on site. The company pairs advanced interpretation software with a comprehensive genomic knowledgebase to empower clinicians to understand genetic variation and inform treatment decisions. PierianDx partners with industry leaders and medical facilities worldwide as they build or expand precision medicine programs. The firm was founded in 2014 as a technology-transfer spinout from Washington University in St. Louis and is headquartered in St. Louis. Management says the business is expanding commercially as more healthcare organizations seek to internalize NGS testing capabilities. The recent financing is intended to fund commercial expansion and continued product and team development to bring genomics into more clinical settings. PierianDx offers a SaaS clinical genomics informatics platform that enables the practice of clinical next-generation sequencing (NGS) as a standard of care and supports advanced molecular diagnostic laboratories. The company also operates a CAP- and CLIA-accredited laboratory and provides integrated reporting and decision-support across the clinical care spectrum. PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Leadership emphasizes adding clinical expertise and resources to drive adoption of clinical NGS globally. Management plans to accelerate commercial expansion across the U.S. and international markets including Europe, Asia, Australia, and Latin America. PierianDx was founded in 2014 out of Washington University in St. Louis. PierianDx provides genomic software and services to enable data-driven personalized medicine. Its flagship platform, Clinical Genomicist Workstation (CGW), delivers data-driven workflows for health systems, academic medical centers, and commercial labs to support genomic analysis, interpretation and reporting. Led by CEO Ted Briscoe, the company focuses on improving patient outcomes through precise genomic analysis. PierianDx said it will use the new funding to accelerate product development and expand sales, marketing and operations. The company raised $9.25M in a Series A to support these initiatives.

Participated · Series B · Oct 2021

Led by founder and CEO David Benshoof Klein, Click Therapeutics develops, validates, and commercializes regulated, clinically validated prescription mobile applications intended to treat unmet medical needs. The company uses a proprietary platform-based approach that leverages patient-centric design and AI-based technologies to drive engagement and clinical outcomes. Its pipeline spans indications in psychiatry, neurology, oncology, immunology, and cardiometabolic disease. Click has secured FDA authorizations for CT-132 (episodic migraine) and Rejoyn (major depressive disorder, co-developed with Otsuka Pharmaceuticals). The company holds an IP portfolio that includes 63 granted patents. Financially, Click recently closed a $50M Series D led by Boehringer Ingelheim and previously completed a strategic partnership and Series C financing with Medidata and Dassault Systèmes. As part of the latest transaction, Boehringer agreed to transfer full commercial and marketing authorization rights for CT-155 to Click, positioning the company for commercialization activities.